In brief
- HRSA’s notice published on 14 July 2026 requested input on training and ambulatory models for potential future approved psychedelic therapies, with a consideration deadline of 13 August.
- Psychedelic Alpha reported 59 comments on 20 August. This is a historical count attributed to that outlet, not a docket total measured today.
- The consultation requests information; it does not approve drugs, impose training requirements or guarantee final guidance.
HRSA’s official notice 2026-14146, published on 14 July, requested information on training and care models for potential future FDA-approved psychedelic therapies. The stated consideration deadline was 13 August. Psychedelic Alpha reported 59 comments on 20 August; this review does not recapture the current total or treat that count as a population-majority position.
Who responded and what they said
Psychedelic Alpha’s public section lists developers, associations, clinical operators, nonprofits and state-regulated psilocybin programmes in Oregon and Colorado. The official notice groups questions into training before, during and after administration; community, rural and other clinic settings; and technology-enabled scalability, including AI with oversight and safeguards. These are open questions, not adopted requirements.
The policy context cited in the notice
The notice cites the 18 April federal executive order as context for potential care models. This does not mean HRSA approves medicines or that regulatory details are settled. Experience from supervised psilocybin services can contribute accounts, but contributor categories do not make every opinion clinical evidence or validate a particular model.
What it implies
The notice requests information and does not itself impose clinical policy. Assessing specific positions would require reading the relevant submissions; this review consulted only the public analysis section, not paid content or the entire docket. Later HRSA publications were not checked, so no current absence of a summary or guidance is asserted.
Source
- Psychedelic Alpha. Credentials, Clinics, and Costs: Stakeholders Respond to HRSA’s Psychedelic Therapy RFI. Psychedelic Alpha, August 20, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
